NCT00121251 2021-04-06Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney CancerNational Cancer Institute (NCI)Phase 1/2 Completed17 enrolled 13 charts